EMA Recommends Extension of Therapeutic Indications for Cetuximab By Ogkologos - August 14, 2026 90 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of adult patients with BRAF V600E-mutated mCRC in combination with encorafenib Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... February 22, 2023 Health inequalities: “We have a moral duty to reduce them” February 15, 2022 No Link Between Caffeine Consumption and Breast Cancer, Study Finds September 29, 2021 Happy Holidays from the OncoLink Team December 7, 2023 Load more HOT NEWS How to Support a Spouse or Partner During Cancer Treatment by... A Pet Pug Helped Two Sisters Realize They Both Had Breast... New tool to tackle gaps in public’s knowledge of blood cancer... Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome?
